Abstract
Overview
Introduction
Slow generic uptake, reformulations, follow-on products and new market
entrants will ensure steady long-term growth of the epilepsy market despite
several high profile patent expiries. UCB has emerged as the number one
epilepsy company, and is set to strengthen their epilepsy pipeline if the
proposed acquisition of Schwarz is confirmed.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
epilepsy
- Overview of drugs in pre-registration, Phase III, II and I; with analysis
of key companies involved in the market
- Detailed profiles of key compounds in development for use in epilepsy,
with forecasts of drug revenues to 2015
- Discussion of UCB, Eisai, and GSK' s strategies and insight from key
industry opinion leaders
Highlights
Following on from Keppra' s commercial success, UCB is the current epilepsy
market leader. UCB' s existing relationship with neurologists will bode well
for the potent follow-on compounds, brivaracetam and seletracetam.
UCB' s proposed acquisition of Schwarz will further boost its epilepsy pipeline
and CNS marketing/sales capabilities. If the acquisition is completed,
Datamonitor believes that UCB will continue to develop Schwarz' s Phase III
pipeline product lacosamide.
Generic incursion in the epilepsy market is less profound than in other CNS
sectors. Nevertheless, lifecycle management strategies will be necessary to
maintain market share following patent expiries. For example, development of
sustained release/extended release formulations such as GSK' s Lamictal XR can
slow generic incursion.
Reasons to Purchase
- Understand unmet needs in the epilepsy market based on key opinion leader
comments
- Benchmark key late-stage epilepsy compounds against current market leaders
- Assess the global (US, Japan, five major EU) sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
View Cart
